Arimidex is used mainly for hormone receptor-positive breast cancer in postmenopausal women. By reducing oestrogen stimulation, it can help slow the growth of cancer cells.
Arimidex is used mainly for hormone receptor-positive breast cancer in postmenopausal women. By reducing oestrogen stimulation, it can help slow the growth of cancer cells.
Arimidex lowers oestrogen production in the body by blocking aromatase, an enzyme involved in making oestrogen after menopause.
Arimidex contains anastrozole, a non-steroidal aromatase inhibitor taken as an oral tablet. It is used in selected cases of hormone receptor-positive breast cancer, also called oestrogen receptor-positive or ER-positive disease. These cancers have receptors that can receive growth signals from oestrogen.
| Active ingredient | Drug class | Main clinical role |
|---|---|---|
| Anastrozole | Aromatase inhibitor | Endocrine treatment for selected hormone-sensitive breast cancer |
The product card provides the formulation and strength details for the tablets. Treatment suitability depends on pathology, receptor testing, menopausal status, previous treatment and the oncology plan. Arimidex does not treat every type of breast cancer.
Anastrozole reduces the amount of oestrogen made outside the ovaries. After menopause, much of the body’s oestrogen comes from the conversion of other hormones in fatty tissue, muscle and other sites. Aromatase inhibitors block that conversion.
Arimidex is normally prescribed as part of specialist-led hormone therapy. It may be used after surgery and other initial treatment, or for advanced disease when an oncologist considers endocrine treatment appropriate. The European Medicines Agency describes anastrozole as an aromatase inhibitor for postmenopausal women with hormone-sensitive breast cancer [1]. Treatment decisions are reviewed during follow-up. Tolerability and tumour response help guide later adjustments.
An oncologist confirms suitability through the pathology report and receptor testing. The clinical team may also consider tumour stage, lymph-node involvement, previous endocrine treatment, bone health, liver function and other medicines.
A receptor-positive result means the tumour cells carry hormone receptors that may respond to reduced oestrogen stimulation. A receptor-negative tumour may require a different treatment strategy.
Arimidex is used in specialist oncology settings for primary and metastatic breast cancer when the tumour is hormone-sensitive and the patient is suitable for aromatase inhibition. Treatment may form one part of a wider plan involving surgery, radiotherapy, chemotherapy or another endocrine treatment.
| Treatment setting | Clinical purpose | Main decision factors |
|---|---|---|
| Primary breast cancer | Reduce the risk of recurrence after initial treatment | Receptor status, menopause, stage and previous therapy |
| Advanced breast cancer | Slow hormone-sensitive disease and control symptoms | Extent of disease, prior treatment and general health |
Primary breast cancer is disease that began in the breast and has not spread to distant organs. After surgery, Arimidex may be used as adjuvant endocrine therapy when pathology shows hormone sensitivity.
The aim is to reduce the chance of recurrence, not to guarantee that recurrence will never occur. Duration and treatment sequence depend on the oncology plan. Some patients receive endocrine therapy after chemotherapy or radiotherapy, while others follow a different sequence.
Metastatic, or secondary, breast cancer has spread beyond the breast and nearby lymph nodes to another part of the body. Arimidex may be considered when the disease remains hormone-sensitive.
The goals may include slowing progression, controlling symptoms and maintaining daily function. An oncologist may combine endocrine treatment with another cancer therapy, depending on prior treatment and tumour characteristics.
Estradiol is a major form of oestrogen. Arimidex lowers estradiol mainly by reducing peripheral production, which is the principal source of oestrogen after menopause.
A reduction in oestrogen may contribute to hot flushes, vaginal dryness, changes in mood, joint discomfort and loss of bone mineral density. These effects vary widely between patients and do not provide a precise measurement of hormone levels.
Blood tests may be used in selected situations, especially when menopausal status is uncertain. Results require clinical interpretation because ovarian activity, other medicines and the timing of testing can affect the picture.
Before menopause, the ovaries produce substantial amounts of oestrogen. An aromatase inhibitor alone may therefore be unsuitable for a premenopausal patient because ovarian production can continue.
Some premenopausal patients receive ovarian suppression through a specialist-directed injection or another endocrine method before an aromatase inhibitor is considered. Ovarian suppression and aromatase inhibition are different treatments. The oncology team determines whether both are needed.
Arimidex is taken orally, usually once daily, at the dose selected by the oncology team. The dose is decided individually after considering age, other medicines and health conditions.
A consistent routine can reduce missed doses. Pairing the tablet with a regular daily activity, such as breakfast or brushing teeth, may help. Patients managing several medicines often benefit from a simple written record, especially during travel or hospital appointments.
Arimidex is not suitable in several situations:
The HPRA provides medicine-safety information for medicines used in Ireland, while the EMA product information covers contraindications, interactions and adverse reactions. The choice between endocrine treatments also depends on anticoagulants, osteoporosis medicines, corticosteroids and other prescription or non-prescription products.
NOT for you if you are pregnant or breastfeeding, premenopausal without appropriate ovarian suppression, allergic to anastrozole, or have a treatment plan that makes aromatase inhibition unsuitable; discuss alternatives with the oncology team.
Anastrozole can cause oestrogen-related effects because it lowers circulating oestrogen. Common problems include hot flushes, sweating, joint pain, muscle pain, stiffness, tiredness, headache, mood changes and vaginal dryness.
Joint and muscle symptoms can affect sleep, mobility and willingness to continue treatment. Persistent discomfort deserves early discussion because a manageable side effect can gradually lead to missed doses if it remains untreated.
Other clinically relevant concerns include reduced bone mineral density, osteoporosis, fractures, changes in cholesterol and liver-enzyme abnormalities. The product information also identifies hypersensitivity and pregnancy-related restrictions as important safety considerations [2].
Patients may be offered bone-density assessment or follow-up blood tests according to their risk profile. A new, persistent pain in the hip, back or wrist should not be dismissed as ordinary stiffness.
Cancer itself, reduced mobility, surgery and some treatments can affect clot risk. Anastrozole is not defined by blood clots in the same way as some other endocrine treatments, but suspected thrombosis still requires urgent assessment.
Symptoms of deep vein thrombosis, or DVT, can include:
A clot that travels to the lungs is called a pulmonary embolism, or PE. Sudden breathlessness, sharp chest pain, fainting or coughing blood requires emergency services in Ireland.
Lower oestrogen can accelerate bone loss in some patients. Risk is greater with previous osteoporosis, low body weight, smoking, heavy alcohol use, long-term steroid treatment or a history of fractures.
Cholesterol and liver health may also require monitoring. Severe or persistent tiredness, yellowing of the skin, dark urine or unusual abdominal discomfort should be reported promptly.
Arimidex does not remove all oestrogen from the body. Instead, anastrozole blocks aromatase, a protein that enables the chemical conversion of androgen precursors into oestrogen. Lower oestrogen exposure can reduce stimulation of ER-positive breast cancer cells.
An enzyme is a protein that helps a chemical reaction take place. Aromatase helps produce oestrogens such as estradiol in tissues outside the ovaries.
Anastrozole attaches to the aromatase system and inhibits its activity. This lowers peripheral oestrogen production, especially after menopause, when ovarian oestrogen production has naturally declined. The effect develops through continued treatment rather than producing an immediate change in a tumour.
The National Cancer Institute and the World Health Organization describe endocrine treatment as a way of altering hormone signalling in hormone-sensitive cancers. The response of an individual tumour still depends on its biology and treatment history.
ER-positive breast cancer cells use oestrogen-receptor signalling to support growth and survival. Reducing circulating oestrogen can weaken that signal.
Symptoms alone cannot show whether blood oestrogen has fallen sufficiently. Laboratory results, treatment history and clinical assessment provide a more reliable basis for decisions. Anastrozole is less relevant to hormone receptor-negative disease because reducing oestrogen does not target the same growth pathway.
Several practical errors can reduce treatment continuity:
Symptoms do not reliably show how much oestrogen has fallen or whether a tumour is responding. Imaging, pathology, examination and oncology follow-up provide the relevant clinical information.
Arimidex is the product name associated with anastrozole. Tamoxifen is a different type of hormone therapy. Anastrozole reduces oestrogen production, while tamoxifen blocks oestrogen receptors in breast tissue.
| Treatment | Main mechanism | Common clinical considerations |
|---|---|---|
| Anastrozole | Reduces peripheral oestrogen production | Often used after menopause; bone and joint effects require attention |
| Tamoxifen | Blocks oestrogen receptors | Can be used in several menopausal settings; clot and uterine risks require assessment |
Neither treatment is universally preferable. Selection depends on menopausal status, tumour features, previous treatment, bone health, clot risk, uterine health, other medicines and individual tolerability.
Tamoxifen may be associated with hot flushes and other endocrine effects, as well as important clot and uterine considerations. Aromatase inhibitors are more closely associated with joint symptoms and bone loss. These are population-level patterns, not predictions of one person’s experience.
In clinical practice, oncologists focus on two linked questions: whether the treatment matches the tumour biology and whether the patient can continue it consistently. A technically appropriate treatment has limited value when pain, fatigue or mood changes lead to silent non-adherence.
Doctors commonly review symptoms, bone health, cardiovascular risk, liver function and other medicines during follow-up. They may also ask about missed tablets rather than assuming that a prescription means every dose has been taken.
The treatment plan can change if the balance between benefit and tolerability changes. Such decisions may involve switching endocrine therapy, adding bone protection or treating a specific adverse effect. A patient should not make that change alone.
Alcohol is not automatically prohibited with anastrozole, but regular heavy drinking can worsen sleep, hot flushes, fatigue and liver strain. The HPRA product information reviewed in 2025 advises attention to liver-related safety and concurrent medicines. A person receiving cancer treatment should also consider falls, bone health and other medicines when deciding whether to drink.
Arimidex changes aromatase activity after treatment begins, but patients may not feel a direct sign that the medicine is working. The EMA endocrine-treatment information reviewed in 2025 explains that clinical benefit is assessed through follow-up rather than symptoms alone. Tumour response and recurrence-risk reduction are evaluated over time with oncology examinations, imaging and other relevant tests.
Sudden breathlessness, chest pain, coughing blood, fainting or one-sided leg swelling can indicate a serious clot and require emergency services in Ireland. The WHO cancer-treatment safety principles reviewed in 2025 support urgent assessment of severe breathing or circulation symptoms. Severe allergic swelling, difficulty breathing or signs of serious liver injury also require immediate medical attention; do not take another dose until urgent clinical advice has been obtained.
Anastrozole is not generally tapered in the same way as medicines that cause a withdrawal syndrome, but stopping it can remove the intended oestrogen-lowering treatment effect. National Cancer Control Programme guidance reviewed in 2025 recommends that endocrine-treatment changes are planned with the treating team. The reason for stopping may affect whether another hormone therapy, a treatment break or additional monitoring is appropriate.
The tablet should be swallowed as directed unless a pharmacist or prescriber confirms that alteration is suitable for the specific formulation. The EMA product information reviewed in 2025 provides the authorised administration instructions for anastrozole tablets. Crushing or chewing can make swallowing more difficult and may lead to an incorrect dose being taken, so do not alter the tablet as a routine workaround.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 3 reviews
I had started Arimidex after surgery and found the first month difficult because my hands felt stiff in the morning. Gentle movement helped, but the useful change came after I reported it and my team reviewed my plan.
The first month 7 Oct 2026I took my tablet after breakfast and missed several doses during a hospital admission because my routine changed. Writing down each dose afterwards made things much easier, although the joint aches still needed attention.
20 Oct 2026My treatment was linked to ovarian suppression rather than a simple postmenopausal plan. I initially expected quick changes, but the oncology team explained that symptom changes do not measure tumour response.
4 Nov 2026
